Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 3
2016 3
2017 8
2018 4
2019 5
2020 6
2021 3
2023 6
2024 4
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Janjigian YY, et al. N Engl J Med. 2025 Jul 17;393(3):217-230. doi: 10.1056/NEJMoa2503701. Epub 2025 Jun 1. N Engl J Med. 2025. PMID: 40454643 Clinical Trial.
Tumor-induced natural killer cell dysfunction is a rapid and reversible process uncoupled from the expression of immune checkpoints.
Pouxvielh K, Marotel M, Drouillard A, Villard M, Moreews M, Bossan A, Poiget M, Khoryati L, Benezech S, Fallone L, Hamada S, Rousseaux N, Picq L, Rocca Y, Berton A, Teixeira M, Mathieu AL, Ainouze M, Hasan U, Fournier A, Thaunat O, Marçais A, Walzer T. Pouxvielh K, et al. Among authors: drouillard a. Sci Adv. 2024 Aug 30;10(35):eadn0164. doi: 10.1126/sciadv.adn0164. Epub 2024 Aug 28. Sci Adv. 2024. PMID: 39196934 Free PMC article.
[Epidemiology of pancreatic cancer].
Drouillard A, Manfredi S, Lepage C, Bouvier AM. Drouillard A, et al. Bull Cancer. 2018 Jan;105(1):63-69. doi: 10.1016/j.bulcan.2017.11.004. Epub 2017 Dec 19. Bull Cancer. 2018. PMID: 29273548 Review. French.
Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.
Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB. Piquemal D, et al. Among authors: drouillard a. J Gastrointest Oncol. 2023 Apr 29;14(2):997-1007. doi: 10.21037/jgo-22-946. Epub 2023 Apr 10. J Gastrointest Oncol. 2023. PMID: 37201091 Free PMC article.
Pivotal role of exogenous pyruvate in human natural killer cell metabolism.
Kern Coquillat N, Picq L, Hamond A, Megy P, Benezech S, Drouillard A, Lager-Lachaud N, Cahoreau E, Moreau M, Fallone L, Mathieu AL, Bellvert F, Nizard C, Bulteau AL, Walzer T, Marçais A. Kern Coquillat N, et al. Among authors: drouillard a. Nat Metab. 2025 Feb;7(2):336-347. doi: 10.1038/s42255-024-01188-4. Epub 2025 Jan 3. Nat Metab. 2025. PMID: 39753710
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Auvray Kuentz M, Hautefeuille V, de Mestier L, Coutzac C, Lecomte T, Nardon V, Artru P, Turpin A, Drouillard A, Malka D, Tran-Minh ML, Trouilloud I, Lièvre A, Williet N, Pernot S, Touchefeu Y, Taieb J, Hammel P, Zaanan A. Auvray Kuentz M, et al. Among authors: drouillard a. Int J Cancer. 2023 May 1;152(9):1894-1902. doi: 10.1002/ijc.34414. Epub 2023 Jan 3. Int J Cancer. 2023. PMID: 36562310 Free article.
Immune-checkpoint inhibition for digestive cancers.
Manfredi S, Drouillard A. Manfredi S, et al. Among authors: drouillard a. Lancet Oncol. 2017 May;18(5):561-562. doi: 10.1016/S1470-2045(17)30188-2. Epub 2017 Mar 15. Lancet Oncol. 2017. PMID: 28314687 No abstract available.
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.
Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, Pietrantonio F, Antista M, Ghelardi F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanan A. Bergen ES, et al. Among authors: drouillard a. Gastric Cancer. 2023 May;26(3):425-437. doi: 10.1007/s10120-023-01374-5. Epub 2023 Mar 7. Gastric Cancer. 2023. PMID: 36881202
Epidemiology and risk factors for oesophageal adenocarcinoma.
Lepage C, Drouillard A, Jouve JL, Faivre J. Lepage C, et al. Among authors: drouillard a. Dig Liver Dis. 2013 Aug;45(8):625-9. doi: 10.1016/j.dld.2012.12.020. Epub 2013 Feb 28. Dig Liver Dis. 2013. PMID: 23453359 Review.
43 results